M. Westerhausen

649 total citations
50 papers, 428 citations indexed

About

M. Westerhausen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hematology. According to data from OpenAlex, M. Westerhausen has authored 50 papers receiving a total of 428 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 10 papers in Hematology. Recurrent topics in M. Westerhausen's work include Cancer Treatment and Pharmacology (7 papers), Colorectal Cancer Treatments and Studies (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). M. Westerhausen is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Colorectal Cancer Treatments and Studies (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). M. Westerhausen collaborates with scholars based in Germany, Switzerland and United States. M. Westerhausen's co-authors include G. Meuret, Hans‐Joachim Schmoll, Patrick Schöffski, U. Schubert, H. Wilke, M. Schroeder, Reinhard Andreesen, C. Käufer, G. Schott and Hartmut Hecker and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

M. Westerhausen

45 papers receiving 392 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. Westerhausen Germany 11 212 116 87 73 59 50 428
Mary‐Anne Kedda Australia 12 145 0.7× 108 0.9× 83 1.0× 34 0.5× 33 0.6× 21 449
Greenspan Em United States 10 155 0.7× 69 0.6× 43 0.5× 33 0.5× 64 1.1× 23 400
Takeshi Ohkita Japan 12 155 0.7× 219 1.9× 81 0.9× 182 2.5× 23 0.4× 32 679
DavidS. Alberts United States 9 167 0.8× 135 1.2× 71 0.8× 59 0.8× 67 1.1× 9 455
Jennifer Flatow United States 7 122 0.6× 150 1.3× 28 0.3× 57 0.8× 49 0.8× 7 356
Bernie Fitzharris United Kingdom 10 236 1.1× 111 1.0× 72 0.8× 28 0.4× 32 0.5× 11 474
Н И Переводчикова United Kingdom 5 130 0.6× 121 1.0× 64 0.7× 82 1.1× 15 0.3× 15 429
G Mathé France 9 170 0.8× 120 1.0× 58 0.7× 69 0.9× 40 0.7× 48 386
Risa Tanaka Japan 14 211 1.0× 134 1.2× 106 1.2× 39 0.5× 33 0.6× 52 528
Chabner Ba United States 10 238 1.1× 132 1.1× 56 0.6× 48 0.7× 167 2.8× 21 483

Countries citing papers authored by M. Westerhausen

Since Specialization
Citations

This map shows the geographic impact of M. Westerhausen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Westerhausen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Westerhausen more than expected).

Fields of papers citing papers by M. Westerhausen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Westerhausen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Westerhausen. The network helps show where M. Westerhausen may publish in the future.

Co-authorship network of co-authors of M. Westerhausen

This figure shows the co-authorship network connecting the top 25 collaborators of M. Westerhausen. A scholar is included among the top collaborators of M. Westerhausen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Westerhausen. M. Westerhausen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fuchs, Robyn K., Lothar Leimer, Guido Koch, & M. Westerhausen. (2008). Klinische Erfahrungen mit bakteriell kontaminierten Port-A-Cath-Systemen bei Tumorpatienten. DMW - Deutsche Medizinische Wochenschrift. 112(42). 1615–1618. 1 indexed citations
2.
Mitrou, P.S., Monika Serke, Kenneth L. Becker, et al.. (2008). Mit der HIV-Infektion assoziierte maligne Lymphome. DMW - Deutsche Medizinische Wochenschrift. 116(33). 1217–1223. 1 indexed citations
3.
Hofmann, W.-K., Gerhard Heil, Stephanie A. Wiebe, et al.. (2004). Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Annals of Hematology. 83(8). 498–503. 44 indexed citations
4.
Dierlamm, Judith, Lucienne Michaux, M Stefanova, et al.. (1999). Novel Philadelphia Variant t(Y;9;22)(q12;q34;q11) in a Case of Chronic Myeloid Leukemia. Cancer Genetics and Cytogenetics. 114(2). 150–153. 6 indexed citations
5.
Kleeberg, Ulrich R., E.‐B. Bröcker, R Châtelain, et al.. (1995). Interferon α2b and Fotemustine in Patients with Disseminated Melanoma. Oncology Research and Treatment. 18(5). 456–461. 1 indexed citations
6.
Gabius, Hans‐Joachim, Sigrun Gabius, S. K. Joshi, et al.. (1994). From Ill-Defined Extracts to the Immunomodulatory Lectin: Will There be a Reason for Oncological Application of Mistletoe?*. Planta Medica. 60(1). 2–7. 41 indexed citations
7.
Winkelmann, M., K Ebeling, G Strohmeyer, et al.. (1992). Treatment results of the thioether lipid ilmofosine in patients with malignant tumours. Journal of Cancer Research and Clinical Oncology. 118(6). 405–407. 13 indexed citations
8.
Abken, Hinrich, et al.. (1990). AGGRESSIVE HEPATITIS IN A PATIENT WITH ACUTE MYELOID LEUKAEMIA DURING COMPLETE REMISSION AND DETECTION OF EPSTEIN‐BARR VIRUS DNA IN A LIVER BIOPSY. British Journal of Haematology. 76(4). 557–558. 3 indexed citations
9.
Schmidt, Ulrich, et al.. (1990). Acute Megakaryoblastic Leukemia: A Case Report. Hämatologie und Bluttransfusion. 33. 362–367. 1 indexed citations
10.
Fritze, Dieter, W. Queißer, H. Schmid, et al.. (1986). Prospective Randomized Trial Concerning Hyper- and Normoprolactinemia and the Use of Bromoergocryptine in Patients with Metastatic Breast Cancer. Oncology Research and Treatment. 9(6). 305–312. 10 indexed citations
11.
Fuchs, Roland J., M. Schroeder, & M. Westerhausen. (1986). Results of ifosfamide-containing chemotherapy in soft tissue sarcomas. Journal of Cancer Research and Clinical Oncology. 111(S1). S31–S31.
12.
Schroeder, M., W Wellens, & M. Westerhausen. (1986). Treatment of unresectable non small cell lung cancer (NSCLC) with cis-platinum/ifosfamide/vindesin. Journal of Cancer Research and Clinical Oncology. 111(S1). S36–S36. 2 indexed citations
13.
Fiebig, H.H., W Wellens, M. Peukert, et al.. (1984). Phase-II-Studie des wasserlöslichen Nitrosoharnstoffes ACNU bei fortgeschrittenen kolorektalen Karzinomen. Oncology Research and Treatment. 7(6). 370–377. 3 indexed citations
14.
15.
Westerhausen, M., et al.. (1983). Therapie-Ergebnisse beim fortgeschrittenen Ovarialkarzinom. Oncology Research and Treatment. 6(4). 206–209. 1 indexed citations
16.
Westerhausen, M., et al.. (1981). Immunological changes following posttraumatic splenectomy. Annals of Hematology. 43(6). 345–353. 7 indexed citations
17.
Meuret, G., et al.. (1977). Determination of the bacteriostatic capacity of neutrophils and monocytes in mixed cell populations. Annals of Hematology. 34(3). 223–226. 3 indexed citations
18.
Müller, S, U. Rother, & M. Westerhausen. (1976). Complement activation by cryoglobulin. Evidence for a pathogenic role of an IgG (kappa) cryoglobulin in cutaneous vasculitis. Clinical & Experimental Immunology. 23(2). 233. 14 indexed citations
19.
Westerhausen, M., et al.. (1975). Haarzell-Leukämie. Acta Haematologica. 53(1). 1–16. 9 indexed citations
20.
Schmitz, Herbert, et al.. (1971). [Studies on antibodies against the Epstein-Barr (EB) and cytomegalovirus (CM) in hemoblastoses and malignant tumors].. PubMed. 77. 754–60. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mary‐Anne Kedda Breakdown of academic impact, for papers by Greenspan Em Breakdown of academic impact, for papers by Takeshi Ohkita Breakdown of academic impact, for papers by DavidS. Alberts Breakdown of academic impact, for papers by Jennifer Flatow Breakdown of academic impact, for papers by Bernie Fitzharris Breakdown of academic impact, for papers by Н И Переводчикова Breakdown of academic impact, for papers by G Mathé Breakdown of academic impact, for papers by Risa Tanaka Breakdown of academic impact, for papers by Chabner Ba
Rankless by CCL
2026